Compare Ginkgo Bioworks Holdings Inc (DNA) vs EHang Holdings Ltd - ADR (EH) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical outlook and mixed financials. Revenue declined to $418M in 2025 with a net loss of $276M, though gross margins remain strong at 61.5%. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a cautious sentiment.

The outlook is challenged by persistent losses and regulatory scrutiny, but the company's cash position of $1.12B provides some buffer. Investment opportunities lie in the nascent eVTOL market, while risks include execution missteps and intense competition. Analyst consensus is divided, reflecting high uncertainty.